Lilly

It is difficult to argue with the types of results Eli Lily (NYSE: LLY) It has been produced over the past five years. The company was one of the best drug giants, leaving its shares the broader market in dust. Some may argue that it is…

HJBC Roche (OTCQX: RHHBY) shares fell 5% on Wednesday while shares of rivals Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY) gained ground after Reuters reported that positive data from Roche (OTCQX:RHHBY) in July The obesity drug candidate…

Shares of Hims & Hers Health fell more than 6% Tuesday morning in response to Eli Lilly's (NYSE:) latest announcement. Lilly announced that it has launched single-dose vials of its obesity drug, Zebound, at a 50% discount to other…

JHVEphoto Baron This week, he said that ResMed (NYSE:RMD) is trading at a compelling valuation after the stock sold off last month in response to Eli Lilly's positive data.NYSE:LLY) GLP-1 therapy, tirzepatide, in obstructive sleep…

(Reuters) - Eli Lilly and Company said on Monday it will acquire Morphek Holdings Inc (NASDAQ:MLS) for $3.2 billion in cash, giving the U.S. drugmaker access to an experimental drug for a type of inflammatory bowel disease. Shares of drug…

The head of the world's largest drugs company has criticised the UK's planning system, claiming it stifles investment. Dave Ricks, chief executive of Eli Lilly, a maker of obesity drugs, said current planning processes in the UK…

Al-Naylam Pharmaceuticals CompanyNasdaq: ALLNEY) The best-performing large-cap company ($30+ billion) was in the pharmaceutical or biotechnology space in the second quarter, Yield ~58.5% In the period.The biotech company's strong…

jetcityimage Eli Lilly shares (New York Stock Exchange: LLY) and Novo Nordisk (NVO) in recent months, driven by growing demand for the companies' weight-loss/diabetes drugs tirzepatide, also known as Mounjaro and Zepbound, and…

Weight loss translates into profits for investors. Just look at Eli Lilly And Novo Nordisk. Both stocks have risen dramatically thanks in large part to their obesity drugs, with Lilly's stock more than quadrupling and Novo's…

Novo Nordisk A/S raised its earnings forecast as the drugmaker now ships five times more introductory doses of the weight-loss drug Wegovy in the US than at the end of last year. More than 25,000 patients are now starting treatment each…